Bleeding Events and Correlation with Anti-Xa Levels and Therapeutic Nadroparin Dose in Patients with Impaired Renal Function

Abstract

Dutch national guidelines for therapeutic treatment with low-molecular-weight heparins (LWMHs) in patients with renal insufficiency recommend dose adjustment based on observed anti-Xa levels. The literature on the relationship between anti-Xa levels and clinical outcome in terms of bleeding events is inconsistent. The primary aim of this study was to investigate the incidence and correlation of bleeding events in relation to anti-Xa levels in patients with impaired renal function, using therapeutic nadroparin according to the national guidelines. The secondary objective was to investigate the correlation between the LMWH dose and bleeding events. This was a retrospective study of patients with impaired renal function treated with therapeutic nadroparin for which anti-Xa levels were monitored. Bleeding and thrombotic events were assessed for each patient. This study included 243 patients, of whom 61 (25%) had a bleeding event. There was no correlation between anti-Xa levels and the occurrence of bleeding. Although there was no difference in renal function, weight, or body mass index (BMI) between patients with or without a bleeding event, the median dose of nadroparin was significantly higher (p < 0.005) in patients with a bleeding event. In conclusion, for this study population, there was a high incidence of bleeding. No correlation was found between anti-Xa levels and the occurrence of a bleeding event, with the majority of anti-Xa levels being subtherapeutic. However, a correlation was found between the dose and the occurrence of a bleeding event. Therefore, it is questionable whether the focus on monitoring anti-Xa levels is a justified method to reduce the risk of a bleeding event.

Keywords

nadroparin - dose - anti-Xa level - bleeding events

Authors' Contributions

All authors contributed to the design of the study and writing of the article. L.R. performed the statistical analyses.

Data Availability

Data available on request from the authors.

Publication History

Received: 07 February 2025

Accepted: 04 June 2025

Article published online:
23 June 2025

• References

• 1 Benjamin EJ, Blaha MJ, Chiuve SE. et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A report from the American Heart Association. Circulation 2017; 135 (10) e146-e603
• 2 Bell EJ, Lutsey PL, Basu S. et al. Lifetime risk of venous thromboembolism in two cohort studies. Am J Med 2016; 129 (03) 339.e19-339.e26
• 3 Kumbhani DJ, Cannon CP, Beavers CJ. et al. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021; 77 (05) 629-658
• 4 White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (23 Suppl 1): I4-I8
• 5 Rubboli A, Becattini C, Verheugt FW. Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol 2011; 3 (11) 351-358
• 6 Collet JP, Montalescot G, Agnelli G. et al.; GRACE Investigators, The Global Registry of Acute Coronary Events. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. Eur Heart J 2005; 26 (21) 2285-2293
• 7 Monreal M, Falgá C, Valle R. et al.; RIETE Investigators. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006; 119 (12) 1073-1079
• 8 Lim W. Low-molecular-weight heparin in patients with chronic renal insufficiency. Intern Emerg Med 2008; 3 (04) 319-323
• 9 Schmid P, Fischer AG, Wuillemin WA. Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med Wkly 2009; 139 (31-32): 438-452
• 10 Nederlandse federatie van Nefrologie (NfN). Richtlijn Antistolling met laagmoleculairgewicht heparines (LMWH) bij nierinsufficientie [in Dutch]. Nieuwegein, The Netherlands: Nfn; 2012 . Accessed May 22, 2025 at: https://www.nefro.nl/richtlijnen/antistolling-met-lmwh-bij-nierinsuffici%C3%ABntie-2012
• 11 Dutch Internists Association (NIV). Richtlijn antitrombotisch beleid. Behandeling LMWH bij nierfunctiestoornissen en risico op VTE [in Dutch]. Utrecht, The Netherlands: Dutch Internists Association; 2021. . Accessed May 22, 2025 at: https://richtlijnendatabase.nl/richtlijn/antitrombotisch_beleid/therapie_vte/behandeling_vte_met_lmwh_bij_nierfunctiestoornissen.html
• 12 Bara L, Leizorovicz A, Picolet H, Samama M. Post-surgery Logiparin Study Group. Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Thromb Res 1992; 65 (4-5): 641-650
• 13 Paige JT, Gouda BP, Gaitor-Stampley V. et al. No correlation between anti-factor Xa levels, low-molecular-weight heparin, and bleeding after gastric bypass. Surg Obes Relat Dis 2007; 3 (04) 469-475
• 14 Prandoni P, Lensing AW, Büller HR. et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339 (8791) 441-445
• 15 van den Broek MPH, Verschueren MV, Knibbe CAJ. Critical appraisal of evidence for anti-Xa monitoring and dosing of low-molecular-weight heparin in renal insufficiency. Expert Rev Clin Pharmacol 2022; 15 (10) 1155-1163
• 16 Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78 (09) 2337-2343
• 17 Myers GL, Miller WG, Coresh J. , et al.; National Kidney Disease Education Program Laboratory Working Group. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006; 52 (01) 5-18
• 18 Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (11) 2119-2126
• 19 Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8 (01) 202-204
• 20 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
• 21 Walenga JM, Hoppensteadt DA. Monitoring the new antithrombotic drugs. Semin Thromb Hemost 2004; 30 (06) 683-695
• 22 van Uden RCAE, Jaspers TCC, Meijer K. et al. Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort study. Thromb Res 2024; 236: 4-13
• 23 Hornung P, Khairoun M, Dekker FW. et al. Dosage reduction of low weight heparin in patients with renal dysfunction: Effects on anti-Xa levels and clinical outcomes. PLoS ONE 2020; 15 (10) e0239222
• 24 Smit R, van Marum RJ, Péquériaux NCV. et al. Prevalentie van correcte anti-Xa-bloedspiegels bij patïenten met verminderde nierfunctie op basis van dosisadvies conform richtlijn Nederlandse Federatie voor Nefrologie. Dutch Platform Pharmaceut Res 2016; 2022: 10-28
• 25 Favaloro EJ, Bonar R, Aboud M. , et al.; RCPA QAP in Haematology. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. Lab Hematol 2005; 11 (03) 157-162
• 26 Abildgaard A, Madsen SA, Hvas AM. Dosage of anticoagulants in obesity: Recommendations based on a systematic review. Semin Thromb Hemost 2020; 46 (08) 932-969
• 27 van Dongen CJ, Mac Gillavry MR, Prins MH. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 2003; (1): CD003074
• 28 Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis. Drugs 1996; 52 (Suppl. 07) 30-37